Summary of efficacy data
Variable | Dose escalationn = 15 | Dose expansionn = 18 | All patients n = 33 | 800 mg cohort n = 24 | ||
---|---|---|---|---|---|---|
Best overall response, n (%) | ||||||
Complete response | 0 (0) | 1 (6) | 1 (3) | 1 (4) | ||
Partial response | 4 (27)a | 10 (56) | 14 (42)b | 12 (50) | ||
Stable disease | 6 (40) | 2 (11) | 8 (24) | 5 (21) | ||
Progressive disease | 5 (33) | 5 (28) | 10 (30) | 6 (25) | ||
Overall response rate | 4 (27)a | 11 (61) | 15 (45)b | 13 (54) | ||
Clinical benefit rate | 10 (67) | 13 (72) | 23 (70) | 18 (75) | ||
Median PFS (weeks) | 36 | 48 | 36 | 51 | ||
Median duration of response (range)c | 61 (11–100+) | 39 (8–83+) | 42 (8–100+) | 42 (8–100+) |